Clinical Study

A Prospective, Randomized, Blinded, Placebo-Controlled, Phase IIb Trial Of An Autologous Tumor Lysate (Tl) + Yeast Cell Wall Particles (Ycwp) + Dendritic Cells (Dc) Vaccine Vs Unloaded Ycwp + Dc In Stage III And Stage Iv (Resected) Melanoma To Prevent Rec

Posted Date: Oct 25, 2017

  • Investigator: Jeffrey Sussman
  • Specialties: Hematology/Oncology, Oncology, Cancer, Skin Cancer
  • Type of Study: Drug

The purpose of this study is to (1) produce and test a vaccine that is made from patient’s tumor cells and white blood cells to determine if it can prevent melanoma recurrence; (2) to look at the safety of the vaccine; and (3) to look at the immune system’s response to this vaccine. The vaccine is given by injections into patient's skin to see if it will cause development of a positive immune response against the tumor. This response may enable the body to slow or stop any recurrence of the tumor. The vaccine is an investigational drug, meaning it is not approved by the US FDA.


To Be Eligible For This Study, Patients Must Be Being Treated For Stage Iii Or Stage Iv Melanoma That Will Be Surgically Removed (Resected) And At High Risk For Recurrence.


Elios, Cancer, Vaccine, Melanoma

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.